These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 126436)

  • 1. [Clinical conference: Histaaminemia in myeloproliferative syndromes].
    Cadiou M; Ruff F; Meunier F; Attalah N; Bernadou A; Zittoun R; Parrot JL; Bousser J
    Nouv Rev Fr Hematol; 1975; 15(2):261-9. PubMed ID: 126436
    [No Abstract]   [Full Text] [Related]  

  • 2. [Metamorphosis of chronic myeloproliferative diseases].
    Butoianu E; Nicoară S; Coliţă A; Ursea C; Berceanu S
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1983; 35(3):223-32. PubMed ID: 6140716
    [No Abstract]   [Full Text] [Related]  

  • 3. [Association of hemorrhagic and thrombotic phenomena in myeloproliferative syndromes].
    Meschengieser SS; Woods AI; Schattner MA; Lazzari MA
    Medicina (B Aires); 1981; 41 Suppl():267-73. PubMed ID: 6954340
    [No Abstract]   [Full Text] [Related]  

  • 4. Studies on the phagocytic activity of neutrophilic leukocytes.
    Brandt L
    Scand J Haematol Suppl; 1967; 2():1-126. PubMed ID: 5243720
    [No Abstract]   [Full Text] [Related]  

  • 5. [Radioimmunometric determination of histamine in myeloproliferative syndromes].
    Bettelheim P; Valent P
    Wien Klin Wochenschr; 1989 Oct; 101(20):706-10. PubMed ID: 2480027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelets in the myeloproliferative syndrome.
    Weinfeld A; Branehög I; Kutti J
    Clin Haematol; 1975 Jun; 4(2):373-92. PubMed ID: 1102193
    [No Abstract]   [Full Text] [Related]  

  • 7. Blood histamine in the differential diagnosis of myeloid splenomegaly (osteomyelofibrosis) and other myeloproliferative disorders.
    Gingold N
    Rev Roum Med; 1974; 12(1):15-8. PubMed ID: 4533361
    [No Abstract]   [Full Text] [Related]  

  • 8. Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: relationship to platelet number and function.
    Barbui T; Cortelazzo S; Viero P; Bassan R; Dini E; Semeraro N
    Eur J Cancer Clin Oncol; 1983 Nov; 19(11):1593-9. PubMed ID: 6580171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Familial myeloproliferative syndromes. Study of 6 families and review of literature].
    Kaufman S; Brière J; Bernard J
    Nouv Rev Fr Hematol (1978); 1978 Apr; 20(1):1-15. PubMed ID: 353725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comprehensive care of patients with thrombocythemia].
    Hrubisková K; Steruská M; Horváth A
    Vnitr Lek; 1987 Oct; 33(10):872-82. PubMed ID: 3479860
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of beta-catenin in chronic myeloproliferative disorders.
    Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
    Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
    Tefferi A
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Granulocyte clearance and granulocyte kinetics in myeloproliferative syndromes].
    Jungi WF; Meuret G; Senn HJ
    Schweiz Med Wochenschr; 1974 Jan; 104(4):133-5. PubMed ID: 4521299
    [No Abstract]   [Full Text] [Related]  

  • 15. Diagnosis and management of myeloproliferative disorders.
    Laszlo J; Huang AT
    Curr Probl Cancer; 1977 Jul; 2(1):1-42. PubMed ID: 268266
    [No Abstract]   [Full Text] [Related]  

  • 16. [MYELOPROLIFERATIVE SYNDROMES].
    PIRESWDA F
    Folha Med; 1964 Apr; 48():195-201. PubMed ID: 14271209
    [No Abstract]   [Full Text] [Related]  

  • 17. In vitro culture techniques defining biological abnormalities in the myelodysplastic syndromes and myeloproliferative disorders.
    Greenberg PL
    Clin Haematol; 1986 Nov; 15(4):973-93. PubMed ID: 3552351
    [No Abstract]   [Full Text] [Related]  

  • 18. Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity.
    Gersuk GM; Carmel R; Pattamakom S; Challita PM; Rabinowitz AP; Pattengale PK
    Nat Immun; 1993; 12(3):136-51. PubMed ID: 8329837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical aspects of myeloproliferative disorders excluding CML].
    Komatsu N
    Rinsho Ketsueki; 2008 Oct; 49(10):1411-9. PubMed ID: 18833926
    [No Abstract]   [Full Text] [Related]  

  • 20. [The treatment of myeloproliferative syndromes].
    Maurice P
    Schweiz Med Wochenschr; 1975 Oct; 105(40):1269-74. PubMed ID: 1061995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.